Literature DB >> 16930903

C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease.

Christopher D Link1.   

Abstract

Caenorhabditis elegans has been used to model aspects of a number of age-associated neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's diseases. These models have typically involved the transgenic expression of disease-associated human proteins. Here I describe my laboratory's specific experience engineering C. elegans models of Alzheimer's disease, and give a general consideration of the advantages and disadvantages of these C. elegans models. The type of insights that might be gained from using these (relatively) simple models are highlighted. In particular, I consider the potential these models have for uncovering common and unique fundamental toxic mechanisms underlying human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930903     DOI: 10.1016/j.exger.2006.06.059

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  68 in total

1.  Characterization of low molecular weight chemical fractions of dry bean (Phaseolus vulgaris) for bioactivity using Caenorhabditis elegans longevity and metabolite fingerprinting.

Authors:  Meghan M Mensack; Vanessa K Fitzgerald; Matthew R Lewis; Henry J Thompson
Journal:  J Agric Food Chem       Date:  2010-06-09       Impact factor: 5.279

2.  Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.

Authors:  Roongpetch Keowkase; Marwa Aboukhatwa; Yuan Luo
Journal:  Neuropharmacology       Date:  2010-04-24       Impact factor: 5.250

3.  Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans.

Authors:  Luisa Diomede; Paola Rognoni; Francesca Lavatelli; Margherita Romeo; Andrea di Fonzo; Claudia Foray; Fabio Fiordaliso; Giovanni Palladini; Veronica Valentini; Vittorio Perfetti; Mario Salmona; Giampaolo Merlini
Journal:  Worm       Date:  2014-10-30

4.  Using C. elegans for antimicrobial drug discovery.

Authors:  Athanasios Desalermos; Maged Muhammed; Justin Glavis-Bloom; Eleftherios Mylonakis
Journal:  Expert Opin Drug Discov       Date:  2011-06-01       Impact factor: 6.098

Review 5.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.

Authors:  Alicia N Minniti; Macarena S Arrazola; Marcela Bravo-Zehnder; Francisca Ramos; Nibaldo C Inestrosa; Rebeca Aldunate
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

Review 7.  Understanding the molecular basis of Alzheimer's disease using a Caenorhabditis elegans model system.

Authors:  Collin Y Ewald; Chris Li
Journal:  Brain Struct Funct       Date:  2009-12-11       Impact factor: 3.270

8.  Amyloid precursor protein 96-110 and beta-amyloid 1-42 elicit developmental anomalies in sea urchin embryos and larvae that are alleviated by neurotransmitter analogs for acetylcholine, serotonin and cannabinoids.

Authors:  Gennady A Buznikov; Lyudmila A Nikitina; Frederic J Seidler; Theodore A Slotkin; Vladimir V Bezuglov; Ivan Milosević; Lidija Lazarević; Ljubica Rogac; Sabera Ruzdijić; Ljubisa M Rakić
Journal:  Neurotoxicol Teratol       Date:  2008-05-16       Impact factor: 3.763

Review 9.  Modeling molecular and cellular aspects of human disease using the nematode Caenorhabditis elegans.

Authors:  Gary A Silverman; Cliff J Luke; Sangeeta R Bhatia; Olivia S Long; Anne C Vetica; David H Perlmutter; Stephen C Pak
Journal:  Pediatr Res       Date:  2009-01       Impact factor: 3.756

10.  What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?

Authors:  Dawn Teschendorf; Christopher D Link
Journal:  Mol Neurodegener       Date:  2009-09-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.